Stocksigma LogoStocksigma Logo

SMS Pharmaceuticals Posts Strong Q2FY27 Results and Raises FY27 Guidance

SMS Pharmaceuticals reported a 30% YoY rise in Q2FY27 revenue to ₹316.08 crore, driven by volume growth and improved realizations

SMS Pharmaceuticals Posts Strong Q2FY27 Results and Raises FY27 Guidance

SMS Pharmaceuticals Ltd · Investor Presentation · 04 Nov 2026, 11:57 pm

SMS Pharmaceuticals Posts Strong Q2FY27 Results and Raises FY27 Guidance SMS Pharmaceuticals reported a 30% YoY rise in Q2FY27 revenue to ₹316.08 crore, driven by volume growth and improved realizations. EBITDA expanded 40% YoY to ₹67.65 crore with margins expanding 145 bps to 21%, while reported PAT surged 57% YoY to ₹39.57 crore. Management raised FY27 revenue growth and EBITDA margin guidance above earlier targets. Its ₹280 crore capex program remains on track for FY27 completion, targeting 1.75x net asset turnover over 2-3 years alongside scaling its peptides R&D facility.

Original exchange filing (PDF)

More announcements from SMS Pharmaceuticals Ltd

All SMS Pharmaceuticals Ltd announcements